The KRAS G12C inhibitor earned the designation for previously treated advanced pancreatic cancer, one of oncology’s hardest targets, based on early-phase trial data.
Researchers explain how the brain “remembers” a higher body weight and defends it, helping explain why weight often returns after diets — or after stopping drugs like Wegovy.
The all-stock merger of equals unites Supernus’s brain-disorder portfolio with Indivior’s addiction treatments, forming a company with 11 marketed drugs.
Vanderbilt researchers created the first compounds to selectively switch a protein family called TAOK on or off — research tools, not drugs, that could open new Alzheimer’s leads.
A Financial Times report of merger talks sent AstraZeneca stock lower as analysts questioned why the fast-growing company would take on such a deal. Neither firm has confirmed.
In three women with stubborn, antibiotic-resistant infections, pairing viruses that kill bacteria with a microbiome transplant reduced recurrences and antibiotic use — but the study is tiny.
Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.
Hebrew University researchers show that the overactive gene switches driving tumor growth physically strain and snap DNA — a stress point that might be turned against cancer.
By tracking some patients for up to 25 years, Sanger Institute researchers found DNA changes that flag which slow-growing blood cancers will progress — long before symptoms.
The Series C, backed by Eli Lilly and Bristol Myers Squibb, will advance a FAP-targeted radiotherapeutic for sarcoma and expand a pipeline of precision radioligand drugs.
The partnership pairs miRecule’s RNA-design platform with peptide-based delivery to reach tissues current RNA therapies struggle to treat, starting with neuromuscular disease.
The joint investment expands device assembly for Lilly’s KwikPen in the Cincinnati region, adding at least 400 jobs as demand for diabetes and obesity injectables surges.